CEO transition support for boards and CHROs, beyond the succession plan.
A CEO transition plan governs the org chart: the timeline, the successor slate, the announcement. It says nothing about the two people living through it, the chief executive stepping down and the one stepping up. CEREVITY gives boards and CHROs a confidential clinical resource, not executive coaching, for both leaders through the handoff, without creating a new disclosure line on the board's own governance calendar.
CEO transition support is confidential clinical care, not executive coaching, for the CEO leaving the role and the CEO stepping into it, whether the departure is planned or sudden. CEREVITY gives boards and CHROs a private-pay therapy benefit delivered by licensed clinicians through secure telehealth in all 50 states, with no clinical detail reported back to the board.
What CEREVITY is.
A nationwide network of independent licensed clinicians, offered as a confidential benefit around a single high-visibility seat.
CEREVITY is a nationwide network of independent licensed clinicians providing private-pay therapy by secure telehealth across all 50 states. It is not executive coaching, not an app, and not the company's employee assistance program. Each leader in a CEO transition, outgoing or incoming, is matched by hand to a clinician experienced with high-visibility leadership roles, then keeps that clinician over time.
For a board, the model is simple to reason about. Care is private-pay with no insurance claim filed, so nothing routes through the company's health plan and no claim record is created. The benefit sits above the existing EAP rather than replacing it, reserved for the CEO seat specifically during the months on either side of a handoff, when it is most exposed. The result is support a departing or arriving chief executive will actually use, because using it costs nothing in exposure.
Boards rarely run this alone. Many pair it with the work already underway on the search side, coordinating with the retained search firm handling executive onboarding support for the incoming chief executive, while keeping the clinical relationship entirely separate from that process. The same clinical team runs CEREVITY's dedicated CEO therapist practice, so a board asking this question is rarely the first to ask it.
Why a CEO transition is different from a succession plan.
A succession plan is a governance document, reviewed at the board level and built to survive an audit. CEO succession planning answers who takes the seat and when. It says nothing about what happens to the person leaving it or the person walking in, a gap our 2026 Executive Confidant Gap Report documents in detail.
The outgoing CEO carries a specific kind of loss that a severance package does not address. Identity, calendar, staff, and standing disappear on the same day, often while the person is still expected to advise the transition publicly and gracefully. The clinical territory has more in common with therapy for leaders transitioning to retirement than with a severance negotiation, compressed into a single, closely watched event rather than a private decision made on the leader's own timeline.
The incoming CEO's pressure is different but no less real, and it compounds at exactly the moment a board needs the new leader operating at full capacity. The hidden mental health crisis among executives rarely announces itself in a board meeting; it shows up first in judgment and pace, well before it shows up as a resignation.
CEOs at publicly traded U.S. companies left their posts in 2025, the highest annual total since Challenger, Gray & Christmas began tracking CEO turnover in 2002. Source: Challenger, Gray & Christmas, 2025 CEO Turnover Report, February 2026.
Turnover at the top is accelerating industrywide, and the person stepping into the seat is rarely someone who has done the job before. Russell Reynolds Associates' 2025 Global CEO Turnover Index found that 86 percent of new CEO appointments that year were first-time chief executives, meaning most boards are handing the company to a leader learning the role in public, at the exact moment that leader has the fewest people to talk to about it honestly.
A generic EAP, designed for high-volume, short-term employee support, is structurally mismatched to a single high-visibility seat. A departing or arriving CEO will rarely route something this sensitive through a company-branded channel that a member of their own HR team or board can, in principle, see was used. See EAP versus private therapy, an honest comparison for the structural reasons why. The need goes unmet quietly, which is the most expensive way for it to go unmet.
What the org chart doesn't cover.
Eight patterns CEREVITY clinicians see on both sides of a CEO transition, in the language the room actually uses.
Identity loss on the way out
The calendar, staff, and standing disappear on the same day the title does, often while the departing CEO is still expected to be gracious about it in public. The nearest clinical parallel is professional transition anxiety, compressed into a single closely watched event rather than a private decision.
No peer in the building
An incoming CEO has no predecessor to call and a board that evaluates rather than confides. Every hard call in the first year is absorbed alone, the exact pattern leadership isolation therapy exists for.
Imposter pressure in the first year
Most new CEOs have never held the job before. The gap between the confidence the role requires in public and what a first-time chief executive actually feels in private is exactly what imposter syndrome therapy is built to address, and it rarely shows up on a 100-day plan.
The fear of being watched by the board
A board actively evaluating a new CEO's performance, however constructively, removes the safety to be uncertain out loud in the same room where the evaluation happens. Why CEOs hide burnout from boards covers why that instinct is rational, and why it still costs the company.
Decision fatigue during the handoff
The highest volume of consequential decisions in a CEO's tenure often lands in the first and last ninety days: which initiatives survive, which relationships transfer, which commitments the successor inherits. Decision fatigue therapy addresses the specific toll of that compression.
Burnout compounding under scrutiny
Chronic, unmanaged stress does not pause for a transition; if anything, it accelerates under the added weight of being watched. Executive burnout therapy is often the first clinical support either CEO has ever used.
Indecision at exactly the wrong moment
An incoming CEO inheriting a strategy built by someone else can freeze on decisions that would be routine in year three, at the exact moment the board is watching most closely. Therapy for chronic indecision in leadership exists for this specific bind.
Strain at home during the handoff
Relocation, longer hours, and a compressed public spotlight follow both CEOs home. Marriages and families absorb the overflow of a transition that does not pause for either side, which is why couples therapy is part of the same network.
The plan governs the handoff. It does not govern the person handing it off, or the person receiving it.
Session formats built for a board's calendar.
Three lengths, matched to two very different moments in a transition.
The steady cadence of ongoing therapy. Most clients spend most of their care in 50-minute sessions.
For work that needs more room than a standard hour can hold. See 90-minute sessions.
For work that needs uninterrupted time to reach resolution. See 3-hour therapy intensives.
Care is delivered as individual therapy in 50-minute, 90-minute, and 3-hour sessions by secure telehealth, nationwide. An outgoing CEO working through the final weeks of a handoff, or an incoming CEO between board meetings, can do focused work in a single 90-minute or 3-hour block rather than forcing a standing weekly slot that travel will break. Continuity is preserved because each leader keeps the same clinician throughout, and modality is matched at intake rather than assigned. When the departure is unplanned, same-week access is the norm rather than the exception.
Give both CEOs somewhere confidential to go.
A confidential conversation about a board-level transition benefit takes one call. Nothing about it appears on the succession plan or the board minutes.
Start a partnership conversationHow a transitioning CEO is matched.
Every leader in a transition is matched by hand by CEREVITY's clinical leadership, not by an algorithm running against an intake form.
The eligible individual submits a confidential intake form covering presenting issues, modality preference, professional context, and scheduling parameters. Operated by CEREVITY directly, not by a broker.
Intake is reviewed by CEREVITY's clinical leadership against the network's active capacity, current licensure footprint, and modality availability. This is the step that does not exist in an EAP.
A specific clinician is matched to the transitioning CEO, who receives the match with the clinician's profile, modality, and credentials, plus a direct online scheduling link.
Scheduling runs directly through CEREVITY infrastructure with no phone handoff. First sessions are typically scheduled within 5 to 10 business days of the match.
Care continues on the cadence the clinical work requires, in 50-minute, 90-minute, or 3-hour sessions, without an employer-imposed session cap.
Capability comparison for boards and CHROs.
An evaluation framework on the dimensions that matter when scoping CEO transition support at board level. All three models have a place; they are built for different populations.
| Dimension | Typical EAP | Executive-tier platform | CEREVITY |
|---|---|---|---|
| Network model | Broker layer between employer and contractor roster | Single-vendor platform, W-2 or contracted pool | Independent clinical network with direct relationships |
| Clinician assignment | First contractor to reply with availability | Algorithmic matching on intake-form inputs | Clinical review by network leadership |
| Intake and scheduling | Phone handoff to the clinician's line | App-based intake and scheduling | Network-operated intake, direct online scheduling |
| Session formats | Standard 50-minute, capped session counts | Standard 45 to 50-minute sessions | 50-minute, 90-minute, and 3-hour formats, no cap |
| Clinical scope | Acute, broadly applicable concerns | Workforce-wide, executive tier as an upsell | Built around the presenting issues of transitioning CEOs |
| Modality fit | Generalist talk therapy | Generalist therapy with some specialty | CBT, DBT, psychodynamic, IFS, matched at intake |
| Reach | National via roster density | National telehealth, roster variance | All 50 states via telehealth |
| Payment model | Employer-sponsored, in network | Per-employee-per-month seat pricing | Private pay, out of network, partnership agreement |
| Board visibility | Aggregate, broker-mediated | Vendor dashboards with engagement metrics | Administrative reporting only |
| Right fit for | Workforce-wide acute support | Mid-tier ongoing care with an executive add-on | boards and CHROs, end to end |
If you are running a formal evaluation, our notes on what to look for in a private therapy provider cover the procurement side in detail.
What the board sees, and what it does not.
For a CEO transition benefit to work, both the outgoing and incoming CEO have to trust that using it creates no new disclosure line on the board's own calendar. CEREVITY is built around that requirement.
- Confirmation that contracted services were provided to eligible individuals.
- Aggregate utilization at the partnership level, where contractually appropriate.
- Invoicing and eligibility reconciliation.
- Nothing tied to a specific named transitioning CEO's clinical content.
- Whether a specific named transitioning CEO has scheduled, attended, or engaged.
- What clinical issues are being addressed, or which clinician is assigned.
- Session notes, treatment plans, or diagnostic information.
- Any attendance detail at the individual level.
Clinicians are independent licensed professionals operating under their own licensure and the confidentiality and privacy obligations that attach to it. Protected health information is held within the clinical infrastructure, and the agreements governing it are defined in writing before the partnership goes live. Our notice of privacy practices and privacy policy are published in full.
Clinical records, session content, and individual engagement data sit inside the clinical platform. The administrative layer the partner interacts with is structurally separate from the clinical layer.
Eligibility lists are maintained on the partner side and confirmed at the point of intake. Administering eligibility does not require the partner to receive clinical information back.
A Business Associate Agreement is executed where the partnership structure requires it, and whether one applies is a determination made with counsel rather than assumed. The partnership agreement defines the administrative reporting scope in writing before anything goes live. See also our terms of service.
Boards and CHROs frequently ask about downstream exposure before they will raise this with either CEO at all. The question that comes up most is whether therapy shows up on a background check, a live concern for an outgoing CEO whose next board seat depends on a clean public record, and for an incoming CEO already under a first-year microscope. It is answered directly on our site.
What the first 30 days look like.
The hardest part of a board-level partnership is not the contract. It is the period between signature and the first transitioning CEO in care.
A 60-minute kickoff with your team and CEREVITY's partnership lead. We confirm the partnership shape, the eligibility model, the administrative reporting scope, and the internal owner. The BAA, where applicable, is executed.
Your team provides the eligible-individual list. CEREVITY confirms it against the network and establishes the verification path at intake. Only eligibility confirmation flows forward.
CEREVITY provides a confidential, board-level comms template explaining the benefit, the privacy posture, and how to access intake. It is written to be received without stigma.
Eligible individuals begin intake on their own cadence. First sessions are typically scheduled within 5 to 10 business days. By day 30 the partnership is operational and a quarterly review cadence is in place.
The business case for the board.
Continuity through the handoff, protection of the outgoing leader's exit, and confidence in the incoming leader's first year are the levers, and they are the levers governance already runs on.
Continuity through the transition
With public-company CEO exits at a recorded high and the S&P 500's projected annual succession rate rising to 13 percent in 2025 from 10 percent the year before, a board's exposure to a leadership gap is measurably higher than it was two years ago. Confidential clinical care reaches the leader least likely to ask for help, tracked in our Leadership Mental Health Index. A transition benefit is continuity infrastructure for exactly that leader.
Protecting the outgoing CEO's exit
How a departing chief executive leaves shapes how the company, the press, and the next employer read the transition. A leader managing an unacknowledged identity loss is more likely to have that strain show up publicly. Burnout at the top covers why seniority does not make a leader immune to a difficult exit, and confidential support during the handoff is one of the few levers a board actually controls.
Confidence in the incoming CEO's first year
A board that offers confidential clinical support alongside the succession plan signals to the incoming CEO, and to its own directors, that the transition is being managed as a human event and not only a governance one. That signal compounds through the first-year board relationship, while trust between a new CEO and the board is still being established.
Questions boards and CHROs ask first.
Does CEO transition support replace our succession plan?
No. A succession plan governs the org chart: the timeline, the successor slate, the announcement. CEO transition support is the confidential clinical layer underneath it, for the outgoing and incoming CEO as people, not as roles on a chart. The reasoning is set out in why executives do not use your EAP and what to offer instead.
Is this executive transition coaching?
No, and the distinction matters. Executive transition coaching is performance-focused and typically reports progress back to the board or the sponsor. CEO transition support is confidential clinical therapy delivered by licensed clinicians, addressing stress, identity loss, isolation, and the personal weight of the role, with no stakeholder except the CEO. See executive counseling versus executive coaching.
Which CEOs are eligible: the outgoing leader, the incoming leader, or both?
Scope is defined in the partnership agreement, and most boards cover both sides of the transition: the departing chief executive through the exit, and the incoming chief executive through at least the first year. Some boards extend coverage to the CEO's spouse or partner, since a leadership transition rarely stays contained to one person, and both leaders effectively become public figures during the handoff whether they sought that attention or not.
How is confidentiality protected from the board during a CEO transition?
Care is private pay, so no insurance claim is filed and nothing routes through the company's health plan. The board receives administrative confirmation only, never clinical content or attendance detail tied to a named individual. Our notes on setting up confidential therapy for company leadership walk through how boards typically structure this.
How quickly can a CEO be matched to a clinician?
Once the partnership is in place, an individual CEO is matched by hand to an appropriate clinician, typically within days depending on licensure footprint and modality fit. First sessions are usually scheduled within 5 to 10 business days of the match, and sooner when the departure is unplanned. Matching is reviewed by CEREVITY's clinical leadership rather than assigned algorithmically.
Does this work for a planned CEO succession as well as an unplanned departure?
Yes. A multi-year succession timeline and an emergency departure both create the same underlying need: confidential support for the person leaving and the person arriving. The hidden cost of an untreated leader compounds quietly regardless of how much notice the transition gave the board.
What does CEO transition support cost the board?
Structure is agreed in the partnership conversation and depends on how many individuals are covered and for how long. CEREVITY is a private-pay network with transparent fees, so there are no insurance-driven surprises in the accounting. Standard individual rates are published on our pricing page.
How do we begin a CEO transition support engagement?
Start a partnership conversation using the form on this page, by phone at (562) 295-6650, or through the contact page. A member of CEREVITY's clinical leadership will follow up directly and confidentially to scope a benefit that fits the transition timeline.
Start a partnership conversation.
Tell us where the board is in the process and who needs to be covered. If your timeline is already tight, say so on the form and get started directly; a member of CEREVITY's clinical leadership will follow up personally and confidentially.
Further reading and related partnerships.
Research, buyer-side guidance, and the other verticals CEREVITY supports.
Research and reports
For boards and CHROs
Clinical writing
A note on sources.
The public-company CEO turnover figure is drawn from Challenger, Gray & Christmas's 2025 CEO Turnover Report (February 2026), which tracked 446 CEO exits at publicly traded U.S. companies in 2025, the highest annual total since the firm began tracking the data in 2002. The finding that most new CEOs are first-time chief executives is drawn from Russell Reynolds Associates' 2025 Global CEO Turnover Index, and the rising annual succession rate is drawn from The Conference Board's CEO Succession Practices report (November 2025). The structural argument on this page is based on the firsthand experience of CEREVITY clinicians who have served on EAP panels, combined with publicly available vendor materials. Specific contractual scopes, including any Business Associate Agreement, are confirmed in writing in the partnership agreement before a partnership goes live. Additional CEREVITY research is collected in the knowledge base.